Grant

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

CountryUnited States
Deadline2027-01-07 (46 days left)
Published2024-11-18
SectorsHealth & life sciences
SourceGrants.gov (US)

Summary

Funding opportunity PAR-25-069. CFDA: 93.393

The buyer, the value, the full description and the link to the official notice are available with a free account.